Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
128 hedge funds and large institutions have $1.11B invested in Intra-Cellular Therapies Inc. in 2015 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 8 closing their positions.
463% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 8
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
93% more capital invested
Capital invested by funds: $576M → $1.11B (+$538M)
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
41% more funds holding
Funds holding: 91 → 128 (+37)
27% more call options, than puts
Call options by funds: $22.1M | Put options by funds: $17.5M
Top Buyers
| 1 |
TCM
TimesSquare Capital Management
New York
|
+$35.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.7M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$23.2M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$16.5M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
126
Ladenburg Thalmann Financial Services
Miami,
Florida
| $6K | +$4.89K | +150 | New |
|
|
N
127
Nuveen
Charlotte,
North Carolina
| $668 | +$544K | +16,689 | New |
|
128
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $546 | +$11.9K | +366 | +3% |
|
|
PC
129
Pier Capital
Stamford,
Connecticut
| – | -$8.22M | -257,256 | Closed |
|
130
Balyasny Asset Management
Chicago,
Illinois
| – | -$1.63M | -50,000 | Closed |
|
|
NI
131
Numeric Investors
Boston,
Massachusetts
| – | -$834K | -26,100 | Closed |
|
|
CC
132
Callan Capital
La Jolla,
California
| – | -$742K | -23,232 | Closed |
|
|
TI
133
Trexquant Investment
Stamford,
Connecticut
| – | -$677K | -21,200 | Closed |
|
|
NIP
134
Nicholas Investment Partners
Rancho Santa Fe,
California
| – | -$260K | -8,130 | Closed |
|
|
EEG
135
E.E. Geduld
| – | -$241K | -7,530 | Closed |
|
|
NCMW
136
Northern Capital Management (Wisconsin)
Madison,
Wisconsin
| – | -$213K | -6,655 | Closed |
|
ITCI Hedge Fund Activity: Q3 2015 in Review
128 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2015, worth a combined $1.11B — up 93% from $576M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ITCI positions and 8 closed out — a net gain of 37 holders — while 44 added to existing stakes and 31 trimmed.
The largest buyer was TimesSquare Capital Management, opening a new position worth an estimated $35.9M. The largest seller was Pier Capital, exiting entirely with an estimated $8.22M sold.
- 128 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2015, up from 91 in Q2 2015.
- Funds reported $1.11B of Intra-Cellular Therapies Inc. stock for Q3 2015, up 93% quarter-over-quarter.
- 45 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2015 and 8 closed out, a net change of +37 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2015 was TimesSquare Capital Management, an estimated $35.9M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2015 was Pier Capital, an estimated $8.22M sold.
Based on aggregated 13F filings for Q3 2015.